Arbutus Biopharma Corp (ABUS) Stock Grade

About Arbutus Biopharma Corp's fundamentals

Arbutus Biopharma is a biotechnology company with a market capitalization of $921.6 million that demonstrated strong revenue momentum, growing 128.2% year-over-year. However, the company is currently unprofitable, with a net margin of -237.9%, and reported a net loss in its latest annual statement, indicating it is still in a cash-burn phase typical of earlier-stage biotech firms. The company does not pay a dividend and has a low P/E ratio of 3.3, which reflects the loss-making status rather than indicating valuation strength.